CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Memantinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00264238
NCT00264238Phase 2Completed
CompareCT.gov

An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder

Stanford University·interventional·Posted Dec 12, 2005·Updated May 30, 2017

In Brief

A Phase 2 clinical trial evaluating Memantine for Obsessive-Compulsive Disorder. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObsessive-Compulsive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 12, 2005
Enrollment StartJan 1, 2006
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 20.6 years ago

Interventions

Memantinedrug

pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder